Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20840866
Simoneau M, et al. (2011) SHP-1 inhibits β-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal 23, 269-79 20840866
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
U0126 no effect upon treatment-induced increase
LY294002 vanadate inhibit treatment-induced increase
U0126 LY294002, vanadate no effect upon treatment-induced decrease
PP2 vanadate no effect upon treatment-induced increase

Y86-p - CTNNB1 (human)
Modsite: VADIDGQyAMTRAQR SwissProt Entrez-Gene
Orthologous residues
CTNNB1 (human): Y86‑p, CTNNB1 (mouse): Y86‑p, CTNNB1 (rat): Y86‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (mouse) pharmacological activator of upstream enzyme, transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme, activation of upstream enzyme, mutation in upstream enzyme recognition motif
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
TBN (human) Induces transcription, altered co-immunoprecipitation

Y654-p - CTNNB1 (human)
Modsite: RNEGVAtyAAAVLFR SwissProt Entrez-Gene
Orthologous residues
CTNNB1 (human): Y654‑p, CTNNB1 (mouse): Y654‑p, CTNNB1 (rat): Y654‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE SHP-1 (mouse) pharmacological activator of upstream enzyme, transfection of wild-type enzyme, phospho-antibody, siRNA inhibition of enzyme, activation of upstream enzyme, mutation in upstream enzyme recognition motif
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
TBN (human) Induces co-immunoprecipitation

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
U0126 vanadate inhibit treatment-induced increase
LY294002 vanadate no effect upon treatment-induced increase
LY294002 U0126, vanadate no effect upon treatment-induced decrease
PP2 vanadate no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
U0126 vanadate inhibit treatment-induced increase
LY294002 vanadate no effect upon treatment-induced increase
LY294002 U0126, vanadate no effect upon treatment-induced decrease
PP2 vanadate no effect upon treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
U0126 vanadate inhibit treatment-induced increase
LY294002 vanadate no effect upon treatment-induced increase
LY294002 U0126, vanadate no effect upon treatment-induced decrease
PP2 vanadate no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293T (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
U0126 vanadate inhibit treatment-induced increase
LY294002 vanadate no effect upon treatment-induced increase
LY294002 U0126, vanadate no effect upon treatment-induced decrease
PP2 vanadate no effect upon treatment-induced increase